Please answer the following 2 questions (~few sentences):

-why do you think FDA is approving drugs based on surrogate endpoints

Because surrogate end points can expedite trial completion compared with overall survival (OS). In addition, some surrogate endpoints are correlated with OS.

-do you agree (Yes/No). Why or why not?

I agree that the surrogate endpoint can be used, but only if the surrogate endpoint is shown to be in the causal pathway between treatment and outcome or have high correlation with the outcome of interest. Because otherwise the use of surrogate endpoint adds substantial uncertainty regarding whether the drugs involved improve quantity or quality of life.